United States Natural Gas Fund vs Viatris Inc — how do they compare? United States Natural Gas Fund trades at $10.05, while Viatris Inc trades at $16.45 (market cap $18.95B). The key difference: Viatris Inc pays a 2.91% dividend while United States Natural Gas Fund pays none, and Viatris Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| UNG | VTRS | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $16.90 | $17.86 |
52-Week Low | $9.63 | $9.49 |
Market Cap | — | $18.95B |
Enterprise Value | — | $31.07B |
Dividend Yield | — | 2.91% |
Signals from Pluang's Aura AI — not financial advice
UNG trades at $10.46, down 0.95% with a bearish technical signal from moving averages. The ETF faces headwinds from high natural gas production and storage levels, though weather-driven demand provides some support. Recent EIA forecasts project record natural gas supply and demand through 2027, creating a mixed fundamental backdrop for this futures-based commodity ETF.
The outlook remains challenged by oversupply concerns, though long-term demand growth from LNG exports and data center power needs offers potential upside. Key risks include commodity price volatility and the structural limitations of futures-based ETFs versus equity-based alternatives like FCG.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Trailing returns across standard periods
Latest headlines on both assets
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →